Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Twenty-year Experience With Endoscopic Therapy for Symptomatic Primary Sclerosing Cholangitis

A Twenty-year Experience With Endoscopic Therapy for Symptomatic Primary Sclerosing Cholangitis ORIGINAL ARTICLE A Twenty-year Experience With Endoscopic Therapy for Symptomatic Primary Sclerosing Cholangitis Michael Gluck, MD, Nico R. Cantone, BS, John J. Brandabur, MD, David J. Patterson, MD, James E. Bredfeldt, MD, and Richard A. Kozarek, MD ducts. The majority of patients develop cirrhosis of the Goals: The current study presents 1 tertiary endoscopy center’s liver with 10% to 15% harboring or developing 20-year experience using endoscopic therapy to treat patients cholangiocarcinoma, and an estimated 10% of those with symptomatic primary sclerosing cholangitis (PSC). with underlying inflammatory bowel disease (IBD) will develop colon cancer. Patients can suffer recurrent Background: Endoscopic therapy for patients with PSC and episodes of bacterial cholangitis, formation of bile duct dominant strictures has been used for more than 20 years, but stones, and development of abscesses in the liver proximal there is concern that instrumenting a sclerotic biliary tree to strictures. The only definitive cure for PSC is induces risks that outweigh anticipated benefits. orthotopic liver transplantation. Successful clinical Study: In this retrospective chart review, 117 patients with PSC management of PSC hinges on identifying those patients were identified using ICD-9 codes. Patients had a mean age of 47 who have the highest likelihood of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Gastroenterology Wolters Kluwer Health

A Twenty-year Experience With Endoscopic Therapy for Symptomatic Primary Sclerosing Cholangitis

Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/a-twenty-year-experience-with-endoscopic-therapy-for-symptomatic-7p0t0x6uQ2

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0192-0790
eISSN
1539-2031
DOI
10.1097/MCG.0b013e3181646713
pmid
18580600
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE A Twenty-year Experience With Endoscopic Therapy for Symptomatic Primary Sclerosing Cholangitis Michael Gluck, MD, Nico R. Cantone, BS, John J. Brandabur, MD, David J. Patterson, MD, James E. Bredfeldt, MD, and Richard A. Kozarek, MD ducts. The majority of patients develop cirrhosis of the Goals: The current study presents 1 tertiary endoscopy center’s liver with 10% to 15% harboring or developing 20-year experience using endoscopic therapy to treat patients cholangiocarcinoma, and an estimated 10% of those with symptomatic primary sclerosing cholangitis (PSC). with underlying inflammatory bowel disease (IBD) will develop colon cancer. Patients can suffer recurrent Background: Endoscopic therapy for patients with PSC and episodes of bacterial cholangitis, formation of bile duct dominant strictures has been used for more than 20 years, but stones, and development of abscesses in the liver proximal there is concern that instrumenting a sclerotic biliary tree to strictures. The only definitive cure for PSC is induces risks that outweigh anticipated benefits. orthotopic liver transplantation. Successful clinical Study: In this retrospective chart review, 117 patients with PSC management of PSC hinges on identifying those patients were identified using ICD-9 codes. Patients had a mean age of 47 who have the highest likelihood of

Journal

Journal of Clinical Gastroenterology – Wolters Kluwer Health

Published: Oct 1, 2008

There are no references for this article.